Clinical trials: Recurrent Ovarian Cancer
Low Grade Serous Carcinoma
Ribociclib and Letrozole Treatment in Ovarian Cancer
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
- Trial name
- NCT03673124
- Testing
- Ribociclib, Letrozole
- Where
- 27 sites in United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
This is a study to find out if the study drug, panitumumab, when given with gemcitabine works in treating ovarian cancer and to find out what side effects occur when they are given together.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- PanGem (NCT01296035)
- Testing
- Panitumumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
RATIONALE: A gene-modified virus may be able to kill tumor cells without damaging normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of an attenuated oncolytic measles virus therapy and oncolytic…
- Trial name
- NCT00408590
- Testing
- carcinoembryonic antigen-expressing measles virus, oncolytic measles virus encoding thyroidal sodium iodide symporter, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Mayo Clinic
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment
- Trial name
- NCT01611558
- Testing
- Ipilimumab
- Where
- 17 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Ovarian Cancer
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
To learn if adding etigilimab to nivolumab therapy can help to control clear cell ovarian, fallopian tube, and primary peritoneal cancers that are resistant to platinum-based therapy
- Trial name
- NCT05715216
- Testing
- Nivolumab, Etigilimab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
To evaluate the efficacy and safety of anti-PD-1 antibody MK-3475 (pembrolizumab) in combination with gemcitabine and cisplatin chemotherapy in women with recurrent platinum-resistant ovarian cancer.
- Trial name
- PemCiGem (NCT02608684)
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Cedars-Sinai Medical Center
Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial is studying the side effects and how well A6 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT00939809
- Testing
- Urokinase-Derived Peptide A6, Laboratory Biomarker Analysis
- Where
- 16 sites in United States
- Volunteers
- 31 people
- Sponsor
- Gynecologic Oncology Group
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This phase II trial studies the side effects and how well dalantercept works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer that has returned.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01720173
- Testing
- Dalantercept, Laboratory Biomarker Analysis
- Where
- 40 sites in United States
- Volunteers
- 30 people
- Sponsor
- Gynecologic Oncology Group
Fallopian Tube Cancer, Ovarian Cancer
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00114166
- Testing
- topotecan hydrochloride
- Where
- 78 sites in United States
- Volunteers
- 81 people
- Sponsor
- Gynecologic Oncology Group
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
This is a randomized, two-arm, open-label Phase II multicenter study designed to examine the effects of adding bevacizumab to ixabepilone for the treatment of patients who have recurrent or persistent…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03093155
- Testing
- Ixabepilone, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Yale University
Ovarian Cancer
Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)
This multi-centre, non-randomized open phase I/randomized phase II study will be conducted in 70 patients (10 in phase I, 60 in phase II) with platinum-refractory recurrent epithelial cancer of the ovary, fallopian tube or…
- Trial name
- ZACFAST (NCT00862836)
- Testing
- Vandetanib
- Where
- 5 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Genzyme, a Sanofi Company
Ovarian Neoplasms
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
This study will assess the efficacy and safety of pembrolizumab (MK-3475) monotherapy in female participants with recurrent ovarian cancer (ROC) who have received up to 5 prior lines of treatment including platinum-based…
- Trial name
- NCT02674061
- Testing
- Pembrolizumab
- Volunteers
- 376 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer, Carcinoma, Ovarian Epithelial
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation…
- Conditions
- Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
- Trial name
- NCT05116189
- Testing
- Pembrolizumab, Paclitaxel, Bevacizumab
- Where
- 187 sites in United States, Australia and 23 more
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Carcinoma, Primary Peritoneal Carcinoma
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
The purpose of this study is to determine if the combination of bevacizumab and pemetrexed have an effect on recurrent ovarian and primary peritoneal carcinoma by looking at progression and survival at 6 months.
- Trial name
- NCT00868192
- Testing
- Pemetrexed, Bevacizumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Washington University School of Medicine
Fallopian Tube Cancer, Ovarian Cancer
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00522301
- Testing
- sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase II trial studies the effects of acetylcysteine and topotecan hydrochloride on the tumor microenvironment, or cells that make up a tumor, compared to topotecan hydrochloride alone in patients with ovarian…
- Conditions
- Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02569957
- Testing
- Topotecan Hydrochloride, Acetylcysteine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Akt inhibitor MK2206 is a drug that may stop cancer cells from growing by blocking a protein called protein kinase B (AKT) inside the cell.
- Conditions
- Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01283035
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Carcinoma, Breast Cancer
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
This is a Phase II, open label, non randomized correlative study of AZD2281 in patients with recurrent breast and ovarian cancer in both BRCA inherited mutation carriers and non-carriers to identify objective response rate and to…
- Trial name
- NCT00679783
- Testing
- AZD2281
- Where
- 6 sites in Canada
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Ovarian Cancer
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with platinum-resistant or refractory recurrent ovarian cancer.
- Trial name
- NCT03414047
- Testing
- Prexasertib
- Where
- 46 sites in United States, Australia and 6 more
- Volunteers
- 172 people
- Sponsor
- Eli Lilly and Company
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)